News › Clinical Practice, Industry News, Patient Care

Allergan Launches Juvéderm® VOLITE

January 27, 2017

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today its entry into the skin quality category with the launch of Juvéderm® VOLITE. This is Allergan’s first injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session.This innovative new Allergan product uses the unique patented VYCROSS® technology.
A new innovation for skin quality 
The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. Juvéderm® VOLITE aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Read more at PRNewswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Cold Laser Therapy: The Science and Uses for Med Spas
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
Advertisement